Don’t miss out - Virtual Fundraising Screening Event- the FIRST Australian VIRTUAL SCREENING of Trip of Compassion.

Our previous viewings have sold out within a few days of being announced. Get your ticket early if you missed out!

Mind Medicine Australia is thrilled to welcome you to the premiere virtual screening screening of Trip of Compassion, an acclaimed Israeli documentary on MDMA-assisted psychotherapy for the treatment of Post-Traumatic Stress Disorder (PTSD). Trip of Compassion follows a number of patients participating in clinical trials in Israel, and is the first feature documentary to show footage from within psychedelic-assisted therapy sessions.

“I felt like I went through 15 years of psychological therapy in one night.”
–  Patient featured in Trip of Compassion

You can watch the preview here:

Following the screening there will be a Q & A panel with Dr Ben Sessa, Tania de Jong AM and Peter Hunt AM. This will be an opportunity to engage in a discussion about psychedelic-assisted psychotherapies for mental illness broadly, and what Mind Medicine Australia and other local organisations are doing here in Australia.

"Trip of Compassion is the most compelling movie I've seen in the last  year!"
– Tim Ferris, acclaimed author and podcaster

Director: Gil Karni,
Producers: Zafrir Kochanovsky & Miri Ezra - ttv Productions
Distributors: GO2FILMS

DATE: 17 June 2020

ZOOM SCREENING
Date: Wednesday 17 June 2020
Time: The theatre will open at 7:15pm for 7:30pm start – 9:30pm (incl Q&A Panel)

The screening WILL BEGIN sharp AT 7:30pm (AEST)

Location: Zoom (link and entry code sent with ticket)
Ticket Price: $25 General Admission / $15 Concession

More about medicinal MDMA

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

Results from Phase 2 clinical trials over the past decade have been so compelling that the Food and Drug Administration (FDA) in the United States recently designated MDMA-assisted psychotherapy as a ‘Breakthrough Therapy’. This designation highlights the FDA’s anticipation that these therapies may offer substantial advantage over current treatments. If forthcoming Phase 3 results confirm these treatments are effective, MDMA-assisted treatment of PTSD may become a prescription medicine as early as 2021 in some jurisdictions.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

More about the panel

Dr Ben Sessa (UK)
MBBS BSc MRC Psych
Adolescent and Adult Addictions Psychiatrist Psychedelic Researcher, Bristol University and Imperial College London.

Dr Ben Sessa trained at UCL, London, graduating in Medicine in 1997.

He works clinically as an adult and adolescent psychiatrist, and academically in Bristol and Imperial College London University, with an interest in the developmental trajectory from child maltreatment to adult mental health disorders.

In the last ten years Ben has been a study doctor and a test subject administering and receiving legal doses of pure LSD, psilocybin, MDMA, DMT and Ketamine.

He is currently conducting the world’s first clinical study using MDMA to treat addiction. Ben is the co-founder and past President of the UK’s premier psychedelic research conference, Breaking Convention.
He has published dozens of peer reviewed papers on psychedelics and is the Author of several textbooks, including the influential book ‘The Psychedelic Renaissance‘.

Tania de Jong AM
LL.B (Hons), GradDipMus
Founder & Deputy Chair of Mind Medicine Australia

Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018.

Peter Hunt AM
B.Com, LL.B
Founder & Chair of Mind Medicine Australia

As an investment banker Peter Hunt AM advised local and multi-national companies and governments in Australia for nearly 35 years. He co-founded and was Executive Chairman of one of Australia’s leading investment banking advisory firms, Caliburn Partnership (now called Greenhill Australia) and continued as Chairman of the Firm after its sale to Greenhill Inc in 2009. Peter is an active philanthropist involved in funding, developing and scaling social sector organisations which seek to create a better and fairer world. Peter was made a member of the General Division of the Order of Australia in the Queen’s Birthday Honours List in 2010 for services to the philanthropic sector.

Support psychedelic research and therapy development

By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.
Please click here to make a tax-deductible donation.